CBP

CBP is a leading bi-XDC innovative pharmaceutical company specializing in dual-targeting ligand conjugated drugs. Established in 2016, CBP is committed to the research and industrialization of dual-targeting XDC drugs. The company's management team includes two national-level key talent introduction program awardees, one high-level talent in innovation and entrepreneurship in Jiangsu Province, as well as multiple outstanding professionals in biological R&D, medicinal chemistry, CMC, clinical experts, and business development, all possessing extensive experience in new drug development management both in China and globally. CBP’s proprietary dual-targeting XDC technology platform currently comprises three platforms: the BEST™ technology platform, the C-PROTAC technology platform, and the chronic disease technology platform. Dual-targeting XDC technology is expected to overcome drugability barriers of various molecules with good activity, paving new ways for drug development. The company is not only focused on treating cancers with high incidence rates globally but also actively expanding into other organ delivery and chronic disease treatments. Currently, several pipeline projects are progressively entering the global development stage, with CBP-1008 undergoing Phase Ib clinical trials in fifteen hospitals across China, and CBP-1018 entering the Phase Ia clinical trial stage.